In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

aRigen Pharmaceuticals Inc.

www.arigen.jp

Latest From aRigen Pharmaceuticals Inc.

Insmed plummets on FDA prolonged hold on Arikace programme

Shares of Insmed tumbled as low as 36.8%, or $1.60, on 10 October after the Monmouth Junction, New Jersey-based firm revealed the US FDA plans to continue the clinical hold placed on the company's Phase III trials for Arikace (liposomal amikacin for inhalation) in cystic fibrosis patients with Pseudomonas lung infections.

Orthopedics Respiratory

Deals Shaping the Medical Industry (03/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

aRigen strikes first deal for novel anti-MRSA agent

Green Cross Corp has acquired rights in South Korea to aRigen Pharmaceuticals' lotilibcin (WAP-8294A2), in what is the first licensing deal for the novel anti-MRSA agent.

Infectious Diseases Japan

Deals Shaping the Medical Industry (10/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions
See All

Company Information

  • Industry
  • Biotechnology
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
      • Site Specific
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • aRigen Pharmaceuticals Inc.
  • Senior Management
  • Gensuke Tokoro, Pres. & CEO
    Shigeru Naganuma, Dir. & CFO
    Haruhiko Machida, PhD, Dir. & Chief Dev. Officer
    Masaichi Yamamoto, PhD, Dir. & Chief Rsch. Officer
  • Contact Info
  • aRigen Pharmaceuticals Inc.
    Phone: (81) 3-3470-3310
    6-5-55 Minami Aoyama
    Minato-ku
    Tokyo, 107-0062
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register